Published in Arthritis Rheum on April 01, 1988
Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest (1996) 2.39
Complement and systemic lupus erythematosus. Arthritis Res (2002) 1.58
Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis (1993) 1.12
Anti-C1q antibodies in systemic lupus erythematosus. Lupus (2014) 1.05
Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol (1999) 1.03
Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol (2003) 1.03
Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin Exp Immunol (2003) 0.99
Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol (2012) 0.98
Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin Immunopathol (2005) 0.95
Anti-C1q autoantibodies, novel tests, and clinical consequences. Front Immunol (2013) 0.93
The Pathogenesis of Lupus Nephritis. J Clin Cell Immunol (2014) 0.93
Hypocomplementemic urticarial vasculitis syndrome: a case report and literature review. J Clin Aesthet Dermatol (2012) 0.90
Are anti-C1q antibodies different from other SLE autoantibodies? Nat Rev Rheumatol (2010) 0.87
Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare. Clin J Am Soc Nephrol (2015) 0.84
Antibodies against C1q in anti-glomerular basement membrane nephritis. Clin Exp Immunol (1992) 0.82
Urticarial vasculitis and syndromes in association with connective tissue diseases. Ann Rheum Dis (1991) 0.81
The collagen-like component of the complement system, C1q, is recognized by 7 S autoantibodies and is functionally impaired in synovial fluids of patients with rheumatoid arthritis. Immunology (1996) 0.79
Complete functional C1q deficiency associated with systemic lupus erythematosus (SLE). Clin Exp Immunol (1993) 0.78
Humoral autoreactivity directed against surfactant protein-A (SP-A) in rheumatoid arthritis synovial fluids. Clin Exp Immunol (2000) 0.77
Complement system in dermatological diseases - fire under the skin. Front Med (Lausanne) (2015) 0.76
Fundamental role of C1q in autoimmunity and inflammation. Immunol Res (2015) 0.75
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
Typing of methicillin-resistant Staphylococcus aureus isolates from Düsseldorf by six genotypic methods. J Med Microbiol (1998) 2.39
Specific information concerning taxonomy, pathogenicity and methicillin resistance of staphylococci obtained by a multiplex PCR. J Med Microbiol (1997) 2.16
Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother (1998) 1.91
Biosynthesis of the first component of complement by human and guinea pig peritoneal macrophages: evidence for an independent production of the C1 subunits. J Immunol (1978) 1.79
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood (1995) 1.75
The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother (1998) 1.71
Interaction of the first (C1), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial lipopolysaccharides and with lipid A. J Immunol (1974) 1.69
The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals. J Antimicrob Chemother (1999) 1.68
Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation (2001) 1.64
Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother (1998) 1.61
Antibody-independent interaction of the first component of complement with Gram-negative bacteria. Infect Immun (1978) 1.60
The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother (1998) 1.48
Development of a multiplex-PCR for direct detection of the genes for enterotoxin B and C, and toxic shock syndrome toxin-1 in Staphylococcus aureus isolates. J Med Microbiol (1998) 1.45
Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota. Infect Immun (1981) 1.43
A 66-kilodalton heat shock protein of Salmonella typhimurium is responsible for binding of the bacterium to intestinal mucus. Infect Immun (1992) 1.41
Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J Biol Chem (1996) 1.35
Pneumolysin is the main inducer of cytotoxicity to brain microvascular endothelial cells caused by Streptococcus pneumoniae. Infect Immun (2001) 1.35
Helicobacter pylori: clonal population structure and restricted transmission within families revealed by molecular typing. J Clin Microbiol (2000) 1.25
Detection of 23 immunogenic pneumococcal proteins using convalescent-phase serum. Infect Immun (2000) 1.23
Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation (1997) 1.23
[Measurement of complement with a microliter method]. Z Med Mikrobiol Immunol (1969) 1.22
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry (1976) 1.20
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--I. Effect on fluid phase C1 and on C1 bound to EA or to EAC4. Immunochemistry (1976) 1.20
Interactions between mycoplasma pneumoniae and the first components of complement. Infect Immun (1977) 1.17
Reconstitution of the complement function in C1q-deficient (C1qa-/-) mice with wild-type bone marrow cells. J Immunol (2001) 1.14
Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med (1987) 1.14
Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds. SENTRY Participants Group. Eur J Clin Microbiol Infect Dis (1999) 1.12
PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer (2010) 1.11
Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J Immunol (2000) 1.11
Inflammation in areas of remote changes following focal brain lesion. Prog Neurobiol (2005) 1.11
vacA genotypes and genetic diversity in clinical isolates of Helicobacter pylori. Clin Diagn Lab Immunol (1998) 1.10
The cell wall-associated serine protease PrtA: a highly conserved virulence factor of Streptococcus pneumoniae. FEMS Microbiol Lett (2001) 1.10
Enterotoxin and toxic shock syndrome toxin-1 production of methicillin resistant and methicillin sensitive Staphylococcus aureus strains. Eur J Epidemiol (1997) 1.07
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--II. Effect of polyanions on the binding of C2 to EAC4b. Immunochemistry (1976) 1.07
Killing of the S and Re forms of Salmonella minnesota via the classical pathway of complement activation in guinea-pig and human sera. Immunology (1980) 1.05
Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol (1999) 1.03
Antibody-independent killing of gram-negative bacteria via the classical pathway of complement. Immunol Lett (1987) 1.03
Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either Borna disease or experimental allergic encephalomyelitis. J Neurol Sci (1995) 0.99
Antigenicity, expression, and molecular characterization of surface-located pullulanase of Streptococcus pneumoniae. Infect Immun (2000) 0.98
In vitro chemosensitivity testing of flavone acetic acid (LM975; NSC 347512) and its diethylaminoethyl ester derivative (LM985; NSC 293015). Eur J Cancer Clin Oncol (1987) 0.97
Evidence for direct binding of the first component of complement, C1, to outer membrane proteins from Salmonella minnesota. Curr Top Microbiol Immunol (1985) 0.97
Biosynthesis of the collagen-like C1q molecule and its receptor functions for Fc and polyanionic molecules on macrophages. Curr Top Microbiol Immunol (1983) 0.95
Interaction of purified lipoteichoic acid with the classical complement pathway. Infect Immun (1986) 0.94
The role of accessory cells in polyclonal T cell activation. I. Both induction of interleukin 2 production and of interleukin 2 responsiveness by concanavalin A are accessory cell dependent. Eur J Immunol (1983) 0.94
Requirement for an additional serum factor essential for the antibody-independent activation of the classical complement sequence by Gram-negative bacteria. Infect Immun (1982) 0.93
High-throughput phenotyping of avoidance learning in mice discriminates different genotypes and identifies a novel gene. Genes Brain Behav (2012) 0.93
Strain specificity and cholinergic modulation of visuospatial attention in three inbred mouse strains. Genes Brain Behav (2006) 0.92
Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J Immunol (1982) 0.92
IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts. Clin Exp Immunol (2000) 0.91
Activation of the first component of complement evidence for an internal activation step. J Immunol (1972) 0.91
The classical complement pathway: mechanism of activation of the first component by antigen-antibody complexes. Prog Allergy (1982) 0.89
Autoantibodies to the collagenous region of C1q occur in three strains of lupus-prone mice. Clin Exp Immunol (1996) 0.89
The role of the classical pathway for the bactericidal effect of normal sera against gram-negative bacteria. Curr Top Microbiol Immunol (1985) 0.89
Ultracentrifugation studies on the native form of the first component of human complement (C1). FEBS Lett (1976) 0.89
The first component of complement in serum: evidence for a hitherto unrecognized factor in C1 necessary for internal activation. J Immunol (1973) 0.88
The functions of endogenous C1q, a subcomponent of the first component of complement, as a receptor on the membrane of macrophages. Mol Immunol (1982) 0.88
Gene expression of the A- and B-chain of mouse C1q in different tissues and the characterization of the recombinant A-chain. J Immunol (1991) 0.88
Clinical and immunological studies in a case of selective complete C1q deficiency. Clin Exp Immunol (1979) 0.88
Expression of membrane C1q in human monocyte-derived macrophages is developmentally regulated and enhanced by interferon-gamma. FEBS Lett (2001) 0.87
Differentiation of hemolytically active fluid-phase and cell-bound human C1q by an ant venom-derived polysaccharide. J Immunol (1980) 0.86
Relationship between mutations in the coding and promoter regions of the norA genes in 42 unrelated clinical isolates of Staphylococcus aureus and the MICs of norfloxacin for these strains. J Antimicrob Chemother (1998) 0.86
Contributions of C1q, bacterial lipopolysaccharide, and porins during attachment and ingestion phases of phagocytosis by murine macrophages. Infect Immun (1986) 0.86
The Cl inactivator from guinea pig serum. 3. Characterization and kinetic data of the reaction between the inactivator and EACl and EACl4. Immunochemistry (1972) 0.85
Collagen-like complement component C1q is a membrane protein of human monocyte-derived macrophages that mediates endocytosis. J Immunol (1995) 0.85
Purification and characterization of human, guinea pig and mouse C1q by fast protein liquid chromatography (FPLC). J Immunol Methods (1984) 0.84
Molecular cloning and characterization of the complementary DNA coding for the B-chain of murine Clq. FEBS Lett (1989) 0.84
Complement components C1q, C1r/C1s, and C1INH in rheumatoid arthritis. Correlation of in situ hybridization and northern blot results with function and protein concentration in synovium and primary cell cultures. Arthritis Rheum (1995) 0.84
MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer (2000) 0.84
Insoluble polyanions as activators of both pathways of complement. Immunology (1977) 0.83
Non-sense and missense mutations in the structural genes of complement component C1q A and C chains are linked with two different types of complete selective C1q deficiencies. J Immunol (1995) 0.83
C1 inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein. J Biol Chem (1997) 0.83
Autoreactivity to mouse C1q in a murine model of SLE. Rheumatol Int (1995) 0.83
Functional domains of the human C1q A-chain. Behring Inst Mitt (1993) 0.83
Immunofluorescence studies on the subcomponents of the first component of complement (C1): detection of C1q and C1s in different cells of biopsy material and on human as well as on guinea pig peritoneal macrophages. Immunobiology (1981) 0.83
Mode of interaction of different polyanions with the first (C1,C1) the second (C2) and the fourth (C4) component of complement. IV. Activation of C1 in serum by polyanions. Immunology (1976) 0.83
[Insertion possibility of 16S-23S space amplification and random amplified polymorphic DNA analysis for typing of methicillin-resistant Staphylococcus aureus strains in the context of nosocomial infections]. Zentralbl Hyg Umweltmed (1997) 0.83
Electron microscopic study showing antibody-independent binding of C1q, a subcomponent of the first component of complement, to serum-sensitive salmonellae. Infect Immun (1984) 0.83
Cognitive impact of cytotoxic agents in mice. Psychopharmacology (Berl) (2014) 0.83
Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies. J Clin Invest (1989) 0.83
C1q-bearing immune complexes detected by a monoclonal antibody to human C1q in rheumatoid arthritis sera and synovial fluids. Rheumatol Int (1991) 0.82
Complement component C1 and the collectins: parallels between routes of acquired and innate immunity. Immunol Today (1998) 0.82
[In vitro studies on the mode of action and differences to heparin. Anticomplementary effect of a semisynthetic pentosan-polysulfo-ester]. Z Naturforsch B (1971) 0.82
The reconstitution of human C1, the first complement component: binding of C1r and C1s to C1q influences the C1q conformation. FEBS Lett (1981) 0.82
Inactivation of complement by L-asparaginase preparations not correlated with enzyme content. Nat New Biol (1972) 0.82
Complement component deficiencies and infection: C5, C8 and C3 deficiencies in three families. Eur J Pediatr (1992) 0.82
A rapid and simple ELISA for the determination of duplicate monoclonal antibodies during epitope analysis of antigens and its application to the study of C1(-)-INH. J Immunol Methods (1988) 0.82
A case of selective Clq deficiency. Turk J Pediatr (1979) 0.81
Molecular basis of a new type of C1q-deficiency associated with a non-functional low molecular weight (LMW) C1q: parallels and differences to other known genetic C1q-defects. Immunopharmacology (1997) 0.81
Enzymatic alteration of C1q, the collagen-like subcomponent of the first component of complement, leads to cross-reactivity with type II collagen. FEBS Lett (1988) 0.81
Evidence that C1q, a subcomponent of the first component of complement, is an Fc receptor of peritoneal and alveolar macrophages. Immunobiology (1980) 0.81
Monoclonal anti-mouse macrophage antibodies recognize the globular portions of C1q, a subcomponent of the first component of complement. J Immunol (1984) 0.81
Antibody-independent activation of C1, the first component of complement. Ann Immunol (Paris) (1982) 0.81